New Data on REYOBIQ™ for Leptomeningeal Metastases Presented at the NMN Conference!
Plus Therapeutics is pleased to announce that new clinical data on its lead investigational therapy, REYOBIQ™ (rhenium Re 186 obisbemeda), was presented at the Nuclear Medicine and Neurooncology (NMN) Conference, held May 9–10, 2025.
This presentation included findings from our ongoing ReSPECT-LM Phase 1 clinical trial, which is evaluating REYOBIQ™ for the treatment of leptomeningeal metastases (LM)—a rare and aggressive complication of advanced cancers, such as breast cancer, lung cancer, and melanoma, where cancer cells spread to the membranes surrounding the brain and spinal cord.
What Is REYOBIQ™?
REYOBIQ™ is a targeted radiotherapeutic that uses rhenium-186 to deliver precise radiation directly to cancer-affected areas via intrathecal administration (into the cerebrospinal fluid). This approach allows us to treat leptomeningeal disease more directly and intensively than traditional systemic therapies, while minimizing exposure to healthy tissue.
Encouraging Early Results from ReSPECT-LM
The newly presented data at NMN highlight the safety, tolerability, and early signs of efficacy of REYOBIQ™ in LM patients. These findings are a critical step forward for a patient population that currently has very limited treatment options and poor prognosis.
- Dose dependent increase in the average absorbed dose to the cranial and spinal subarachnoid space reaching 253Gy in Cohort 5
- Neuroimaging response data was available for 17 patients as of the data cutoff with five of those (29%) showing a partial response
- An additional eight patients showed stable disease by neuroimaging through day 112 for a Clinical Benefit Rate (complete response + partial response + stable disease) of 76% (13/17 – five partial responses and eight stable disease). Additionally, 87% of subjects demonstrated clinical response based on the physician evaluation (13/15 – 2 response and 11 stable disease)
- No dose limiting toxicity (DLT) observed in the first four cohorts, with a grade 4 DLT (thrombocytopenia), one in each of Cohorts 5 and 6
- RNA sequencing of LM cells showed early induction of apoptosis, with an innate immune response followed by an increase in T cells and an adaptive immune response by Day 28.
- In addition, of the seven patients who received a response of better than 80% in reduction of LM tumor cells in the cerebrospinal fluid, five survived at least one year following initial treatment.
- The study reports that three of those five were retreated via compassionate use.
Learn more about the ReSPECT-LM trial:
http://respect-trials.com/lm
Contact our clinical team: respect@plustherapeutics.com
#LeptomeningealMetastases #LM #REYOBIQ #Radiotherapeutics #ReSPECTLM #Oncology #CancerClinicalTrials #NMN #PlusTherapeutics #RespectTrials #BreastCancer #LungCancer #CancerResearch #NeuroOncology #CNSMetastases #ClinicalTrialEnrollment
Recent Comments